Experimental Factor Ontology (EFO) Information | |
Identifier | EFO_0000318 |
Description | A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive. [NCIT: C34830] | Trait category |
Cardiovascular disease
|
Synonyms |
24 synonyms
|
Mapped terms |
19 mapped terms
|
Child trait(s) | 2 child traits |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000739 (HCM_GRS) |
PGP000146 | Harper AR et al. Nat Genet (2021) |
Hypertrophic cardiomyopathy | hypertrophic cardiomyopathy | 27 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000739/ScoringFiles/PGS000739.txt.gz | |
PGS000778 (PRSHCM) |
PGP000182 | Tadros R et al. Nat Genet (2021) |
Hypertrophic cardiomyopathy | hypertrophic cardiomyopathy | 20 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000778/ScoringFiles/PGS000778.txt.gz |
PGS003868 (CM_LDpred2_ARB) |
PGP000501 | Shim I et al. Nature Communications (2023) |
Cardiomyopathy | cardiomyopathy | 1,010,014 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003868/ScoringFiles/PGS003868.txt.gz |
PGS004861 (hermes.gwama) |
PGP000608 | Zheng SL et al. medRxiv (2023) |Pre |
Dilated cardiomyopathy | dilated cardiomyopathy | 713,932 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004861/ScoringFiles/PGS004861.txt.gz |
PGS004862 (hermes.mtag) |
PGP000608 | Zheng SL et al. medRxiv (2023) |Pre |
Dilated cardiomyopathy (MTAG) | dilated cardiomyopathy | 709,534 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004862/ScoringFiles/PGS004862.txt.gz |
PGS004946 (DCM_GWAS_exclMGBB) |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Dilated cardiomyopathy | dilated cardiomyopathy | 1,098,677 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004946/ScoringFiles/PGS004946.txt.gz |
PGS004947 (DCM_MTAG_exclMGBB) |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Dilated cardiomyopathy (MTAG) | dilated cardiomyopathy | 1,072,247 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004947/ScoringFiles/PGS004947.txt.gz |
PGS004948 (DCM_GWAS_exclUKB) |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Dilated cardiomyopathy | dilated cardiomyopathy | 1,068,761 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004948/ScoringFiles/PGS004948.txt.gz |
PGS004949 (DCM_MTAG_exclUKB) |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Dilated cardiomyopathy (MTAG) | dilated cardiomyopathy | 1,038,394 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004949/ScoringFiles/PGS004949.txt.gz |
PGS004950 (DCM_GWAS_exclAUMC) |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Dilated cardiomyopathy | dilated cardiomyopathy | 1,098,677 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004950/ScoringFiles/PGS004950.txt.gz |
PGS004951 (DCM_MTAG_exclAUMC) |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Dilated cardiomyopathy (MTAG) | dilated cardiomyopathy | 1,075,760 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004951/ScoringFiles/PGS004951.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM001765 | PGS000739 (HCM_GRS) |
PSS000909| Multi-ancestry (including European)| 41,597 individuals |
PGP000146 | Harper AR et al. Nat Genet (2021) |
Reported Trait: Hypertrophic cardiomyopathy | OR: 1.73 [1.63, 1.83] | — | — | Age, gender, PCs(1-10) | — |
PPM001767 | PGS000739 (HCM_GRS) |
PSS000910| Multi-ancestry (including European)| 20,501 individuals |
PGP000146 | Harper AR et al. Nat Genet (2021) |
Reported Trait: Hypertrophic cardiomyopathy carrying a pathogenic sarcomere mutation | OR: 1.54 [1.39, 1.69] | — | — | Age, gender, PCs(1-10) | — |
PPM001766 | PGS000739 (HCM_GRS) |
PSS000908| Multi-ancestry (including European)| 21,095 individuals |
PGP000146 | Harper AR et al. Nat Genet (2021) |
Reported Trait: Hypertrophic cardiomyopathy in individuals who do not carry a pathogenic sarcomere mutation | OR: 1.8 [1.67, 1.93] | — | — | Age, gender, PCs(1-10) | — |
PPM018527 | PGS000739 (HCM_GRS) |
PSS011008| European Ancestry| 184,511 individuals |
PGP000476 | Biddinger KJ et al. JAMA Cardiol (2022) |Ext. |
Reported Trait: Hypertrophic cardiomyopathy | OR: 1.556 [1.361, 1.778] | — | — | — | — |
PPM018528 | PGS000739 (HCM_GRS) |
PSS011008| European Ancestry| 184,511 individuals |
PGP000476 | Biddinger KJ et al. JAMA Cardiol (2022) |Ext. |
Reported Trait: Hypertrophic cardiomyopathy in noncarriers of an HCM-ACMG rare variant | OR: 1.585 [1.375, 1.828] | — | — | — | — |
PPM018529 | PGS000739 (HCM_GRS) |
PSS011007| European Ancestry| 30,716 individuals |
PGP000476 | Biddinger KJ et al. JAMA Cardiol (2022) |Ext. |
Reported Trait: Hypertrophic cardiomyopathy | OR: 1.35 [1.21, 1.51] | — | — | — | — |
PPM018530 | PGS000739 (HCM_GRS) |
PSS011008| European Ancestry| 184,511 individuals |
PGP000476 | Biddinger KJ et al. JAMA Cardiol (2022) |Ext. |
Reported Trait: Hypertrophic cardiomyopathy | HR: 1.795 [1.521, 2.117] | AUROC: 0.725 [0.678, 0.771] | — | Age, sex, genotyping array, and PCs 1-5 | — |
PPM018531 | PGS000739 (HCM_GRS) |
PSS011008| European Ancestry| 184,511 individuals |
PGP000476 | Biddinger KJ et al. JAMA Cardiol (2022) |Ext. |
Reported Trait: Hypertrophic cardiomyopathy | — | AUROC: 0.821 [0.772, 0.871] | — | Clinical risk factors (obesity, HTN, AF, CAD), HCM-ACMG rare variant carrier status, age, sex, genotyping array, and PCs 1-5 | — |
PPM002016 | PGS000778 (PRSHCM) |
PSS000999| Ancestry Not Reported| 368 individuals |
PGP000182 | Tadros R et al. Nat Genet (2021) |
Reported Trait: Clinical events in individuals with a pathogenic or likely pathogenic sarcomeric variant | HR: 1.28 [1.06, 1.54] β: 0.247 (0.095) |
— | — | Genetic relatedness matrix, sex | Clinical events includes time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter. |
PPM002017 | PGS000778 (PRSHCM) |
PSS001000| Ancestry Not Reported| 368 individuals |
PGP000182 | Tadros R et al. Nat Genet (2021) |
Reported Trait: Major clinical events in individuals with a pathogenic or likely pathogenic sarcomeric variant | HR: 1.29 [1.04, 1.59] β: 0.255 (0.108) |
— | — | Genetic relatedness matrix, sex | Major clinical events includes time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death or appropriate ICD therapy. |
PPM002018 | PGS000778 (PRSHCM) |
PSS001004| Ancestry Not Reported| 368 individuals |
PGP000182 | Tadros R et al. Nat Genet (2021) |
Reported Trait: Septal reduction therapy in individuals with a pathogenic or likely pathogenic sarcomeric variant | HR: 1.36 [1.06, 1.74] β: 0.304 (0.127) |
— | — | Genetic relatedness matrix, sex | Septal reduction therapy includes time time to septal myectomy or alcohol septal ablation. |
PPM002020 | PGS000778 (PRSHCM) |
PSS001003| Ancestry Not Reported| 194 individuals |
PGP000182 | Tadros R et al. Nat Genet (2021) |
Reported Trait: Maximal left ventricular wall thickness indexed to body surface area (mm/m^2) in individuals with a pathogenic or likely pathogenic sarcomeric variant | β: 0.731 (0.238) | — | — | Genetic relatedness matrix | Each standard deviation increase in the polgyenic risk score is associated with 0.7 mm m^-2 increase in maximal left ventricular wall thickness. |
PPM002021 | PGS000778 (PRSHCM) |
PSS001002| Ancestry Not Reported| 214 individuals |
PGP000182 | Tadros R et al. Nat Genet (2021) |
Reported Trait: Clinical events in in individuals with a pathogenic or likely pathogenic sarcomeric variant | HR: 1.53 [1.05, 2.22] β: 0.422 (0.193) |
— | — | Genetic relatedness matrix, sex | Clinical events includes time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter. |
PPM002015 | PGS000778 (PRSHCM) |
PSS001001| Ancestry Not Reported| 322 individuals |
PGP000182 | Tadros R et al. Nat Genet (2021) |
Reported Trait: Maximal left ventricular wall thickness indexed to body surface area (mm/m^2) in individuals with a pathogenic or likely pathogenic sarcomeric variant | β: 0.726 (0.188) | — | — | Genetic relatedness matrix | Each standard deviation increase in the polgyenic risk score is associated with 0.7 mm m^-2 increase in maximal left ventricular wall thickness. |
PPM018760 | PGS003868 (CM_LDpred2_ARB) |
PSS011097| Greater Middle Eastern Ancestry| 2,669 individuals |
PGP000501 | Shim I et al. Nature Communications (2023) |
Reported Trait: Cardiomyopathy | OR: 1.34 [1.13, 1.64] | AUROC: 0.6453 [0.6086, 0.6819] | — | age, sex, array version, and the first 10 principal components of ancestry | — |
PPM021092 | PGS004861 (hermes.gwama) |
PSS011521| European Ancestry| 347,585 individuals |
PGP000608 | Zheng SL et al. medRxiv (2023) |Pre |
Reported Trait: Dilated cardiomyopathy | OR: 1.56 | AUROC: 0.7 | R²: 0.048 | age, age^2, sex, PC1-10 | — |
PPM021093 | PGS004862 (hermes.mtag) |
PSS011521| European Ancestry| 347,585 individuals |
PGP000608 | Zheng SL et al. medRxiv (2023) |Pre |
Reported Trait: Dilated cardiomyopathy | OR: 1.76 | AUROC: 0.71 | R²: 0.05 | age, age^2, sex, PC1-10 | — |
PPM021753 | PGS004946 (DCM_GWAS_exclMGBB) |
PSS011781| Multi-ancestry (including European)| 96,016 individuals |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Reported Trait: Non-ischemic dilated cardiomyopathy | OR: 1.65762 β: 0.5 (0.04) |
— | Univariate (PRS only) AUPRC: 0.0095 Nagelkerke pseudo-R^2 full model: 0.064 Nagelkerke pseudo-R^2 delta PRS/residual: 0.023 Liability-scale R^2 (assuming 0.4% prev) full model: 0.227 Liability-scale R^2 (assuming 0.4% prev) delta PRS/residual: 0.066 Univariate (PRS only) AUC: 0.65 [0.62, 0.67] |
Age, age^2, sex, PC1-12 | beta represents log(OR) per SD of PRS |
PPM021754 | PGS004947 (DCM_MTAG_exclMGBB) |
PSS011781| Multi-ancestry (including European)| 96,016 individuals |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Reported Trait: Non-ischemic dilated cardiomyopathy | OR: 1.73 β: 0.55 (0.04) |
— | Nagelkerke pseudo-R^2 full model: 0.068 Nagelkerke pseudo-R^2 delta PRS/residual: 0.028 Liability-scale R^2 (assuming 0.4% prev) full model: 0.235 Liability-scale R^2 (assuming 0.4% prev) delta PRS/residual: 0.076 Univariate (PRS only) AUC: 0.66 [0.63, 0.68] Univariate (PRS only) AUPRC: 0.0109 |
Age, age^2, sex, PC1-12 | beta represents log(OR) per SD of PRS |
PPM021755 | PGS004948 (DCM_GWAS_exclUKB) |
PSS011782| Multi-ancestry (including European)| 326,106 individuals |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Reported Trait: Non-ischemic dilated cardiomyopathy | OR: 1.64 β: 0.49 (0.04) |
— | Nagelkerke pseudo-R^2 full model: 0.049 Nagelkerke pseudo-R^2 delta PRS/residual: 0.018 Liability-scale R^2 (assuming 0.4% prev) full model: 0.186 Liability-scale R^2 (assuming 0.4% prev) delta PRS/residual: 0.06 Univariate (PRS only) AUC: 0.64 [0.62, 0.66] Univariate (PRS only) AUPRC: 0.0042 |
Age, age^2, sex, array, PC1-12 | beta represents log(OR) per SD of PRS |
PPM021756 | PGS004949 (DCM_MTAG_exclUKB) |
PSS011782| Multi-ancestry (including European)| 326,106 individuals |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Reported Trait: Non-ischemic dilated cardiomyopathy | OR: 1.91 β: 0.65 (0.04) |
— | Nagelkerke pseudo-R^2 full model: 0.06 Nagelkerke pseudo-R^2 delta PRS/residual: 0.029 Liability-scale R^2 (assuming 0.4% prev) full model: 0.216 Liability-scale R^2 (assuming 0.4% prev) delta PRS/residual: 0.095 Univariate (PRS only) AUC: 0.68 [0.66, 0.69] Univariate (PRS only) AUPRC: 0.0052 |
Age, age^2, sex, array, PC1-12 | beta represents log(OR) per SD of PRS |
PPM021757 | PGS004950 (DCM_GWAS_exclAUMC) |
PSS011780| European Ancestry| 7,761 individuals |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Reported Trait: Clinical dilated cardiomyopathy | OR: 1.71 β: 0.54 (0.04) |
— | Nagelkerke pseudo-R^2 full model: 0.101 Nagelkerke pseudo-R^2 delta PRS/residual: 0.052 Liability-scale R^2 (assuming 0.4% prev) full model: 0.13 Liability-scale R^2 (assuming 0.4% prev) delta PRS/residual: 0.073 Univariate (PRS only) AUC: 0.64 [0.62, 0.66] Univariate (PRS only) AUPRC: 0.1765 |
Sex, PC1-12 | beta represents log(OR) per SD of PRS |
PPM021758 | PGS004951 (DCM_MTAG_exclAUMC) |
PSS011780| European Ancestry| 7,761 individuals |
PGP000672 | Jurgens SJ et al. Nat Genet (2024) |
Reported Trait: Clinical dilated cardiomyopathy | OR: 1.93 β: 0.66 (0.04) |
— | Nagelkerke pseudo-R^2 full model: 0.124 Nagelkerke pseudo-R^2 delta PRS/residual: 0.076 Liability-scale R^2 (assuming 0.4% prev) full model: 0.162 Liability-scale R^2 (assuming 0.4% prev) delta PRS/residual: 0.101 Univariate (PRS only) AUC: 0.67 [0.65, 0.69] Univariate (PRS only) AUPRC: 0.2023 |
Sex, PC1-12 | beta represents log(OR) per SD of PRS |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000908 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | African unspecified | — | GEL, RBH-CRB | — |
PSS000908 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | Other admixed ancestry | Ad Mixed American | GEL, RBH-CRB | — |
PSS000908 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | East Asian | — | GEL, RBH-CRB | — |
PSS000908 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | European | — | GEL, RBH-CRB | — |
PSS000908 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | South Asian | — | GEL, RBH-CRB | — |
PSS000908 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | Not reported | — | GEL, RBH-CRB | — |
PSS000909 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | African unspecified | — | GEL, RBH-CRB | — |
PSS000909 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | Other admixed ancestry | Ad Mixed American | GEL, RBH-CRB | — |
PSS000909 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | East Asian | — | GEL, RBH-CRB | — |
PSS000909 | Cases were individuals with hypertrophic cardiomyopathy. In the individuals recruited from the Netherlands, this was identified using current diagnostic criteria(eft ventricular wall thickness ≥15mm or ≥13mm in presence of family history) | — | [
|
— | European | — | GEL, RBH-CRB | — |
PSS000909 | Cases were individuals with hypertrophic Cardiomyopathy. | — | [
|
— | South Asian | — | GEL, RBH-CRB | — |
PSS000909 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | Not reported | — | GEL, RBH-CRB | — |
PSS000910 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | African unspecified | — | GEL, RBH-CRB | — |
PSS000910 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | Other admixed ancestry | Ad Mixed American | GEL, RBH-CRB | — |
PSS000910 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | East Asian | — | GEL, RBH-CRB | — |
PSS000910 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | European | — | GEL, RBH-CRB | — |
PSS000910 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | South Asian | — | GEL, RBH-CRB | — |
PSS000910 | Cases were individuals with hypertrophic cardiomyopathy. | — | [
|
— | Not reported | — | GEL, RBH-CRB | — |
PSS011781 | ICD10 I42.0; excluding antecedent acute coronary disease and/or revascularization | — | [
|
— | European, Not reported | Mostly European-American | AllofUs | — |
PSS011782 | ICD10 I42.0; excluding antecedent acute coronary disease and/or revascularization | — | [
|
— | European, Not reported | — | UKB | Please note: UKB samples included in the first 45k MRI tranche were removed from this testing set, since the MTAG data includes GWAS data of cardiac MRI traits from the UKB. |
PSS011780 | Clinical criteria + imaging | — | [
|
— | European (Dutch) |
— | AUMC_DCM | — |
PSS011097 | — | — | 2,669 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) (Arab) |
— | NR | N total after excluding missing values = 2,553 |
PSS011007 | HCM was defined as having an ICD-10 code of I42.1 or I42.2, in addition to a mention of “hypertrophic cardiomyopathy,” “hypertrophic obstructive cardiomyopathy,” “HCM,” or “HOCM” | — | 30,716 individuals, 45.37 % Male samples |
Mean = 57.23 years | European | — | MGBB | — |
PSS011008 | HCM cases were identified by the presence of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), billing code I42.1 (hypertrophic obstructive cardiomyopathy) or I42.2 (other hypertrophic cardiomyopathy) | — | 184,511 individuals, 45.35 % Male samples |
Mean = 56.51 years | European | — | UKB | — |
PSS011521 | — | — | [ ,
45.8 % Male samples |
Mean = 69.8 years | European | — | UKB | — |
PSS000999 | All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced a clinical event, defined as: time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter. | — | [
|
— | Not reported | — | ERSPC | — |
PSS001000 | All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced a major ventricular arrhythmia, defined as: time to sustained ventricular arrhythmia, appropriate ICD therapy or sudden cardiac death. | — | [
|
— | Not reported | — | ERSPC | — |
PSS001001 | All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). The primary outcome of maximal left ventricular wall thickness is defined as maxLVWT indexed to body surface area (BSA) on last available CMR or TTE prior to septal reduction therapy and cardiac transplantation. LVWT from CMR used whenever available unless TTE performed more than 5 years after last CMR. | — | 322 individuals | — | Not reported | — | ERSPC | — |
PSS001002 | All individuals were non-proband carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced a clinical event, defined as: time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter. | — | [
|
— | Not reported | — | ERSPC | — |
PSS001003 | All individuals were non-proband carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). The primary outcome of maximal left ventricular wall thickness (maxLVWT) is defined as maxLVWT indexed to body surface area (BSA) on last available CMR or TTE prior to septal reduction therapy and cardiac transplantation. LVWT from CMR used whenever available unless TTE performed more than 5 years after last CMR. | — | 194 individuals | — | Not reported | — | ERSPC | — |
PSS001004 | All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced septal reduction therapy, defined as: time to septal myectomy or alcohol septal ablation. | — | [
|
— | Not reported | — | ERSPC | — |